Abstract P6-04-16: Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment

Despite significant advances in treatment strategies over the past decade, selective treatment of breast cancer with limited side-effects still remains a great challenge. The cytochrome P450 (CYP) family of enzymes contribute to cancer cell proliferation, cell signaling and drug metabolism with implications for treatment outcomes. A clearer understanding of CYP expression is important in the pathogenesis of breast cancer as several isoforms play critical roles in metabolising steroid hormones and xenobiotics that contribute to the genesis of breast cancer. The purpose of this review is to provide an update on how the presence of CYPs impacts on standard of care (SoC) drugs used to treat breast cancer as well as discuss opportunities to exploit CYP expression for therapeutic intervention. Finally, we provide our thoughts on future work in CYP research with the aim of supporting ongoing efforts to develop drugs with improved therapeutic index for patient benefit.

Download Full-text

Under-Treatment of Older Patients with Newly Diagnosed Epithelial Ovarian Cancer Remains an Issue

Cancers ◽

10.3390/cancers13050952 ◽

2021 ◽

Vol 13 (5) ◽

pp. 952

Author(s):

Lucy Dumas ◽

Rebecca Bowen ◽

John Butler ◽

Susana Banerjee

Keyword(s):

Ovarian Cancer ◽

Older Women ◽

Older Patients ◽

Single Agent ◽

Eastern Cooperative Oncology Group ◽

Standard Of Care ◽

First Line ◽

Care Treatment ◽

Platinum Based Chemotherapy ◽

Standard Of Care Treatment

Older women with ovarian cancer have disproportionately poorer survival outcomes than their younger counterparts and receive less treatment. In order to understand where the gaps lie in the treatment of older patients, studies incorporating more detailed assessment of baseline characteristics and treatment delivery beyond the scope of most cancer registries are required. We aimed to assess the proportion of women over the age of 65 who are offered and receive standard of care for first-line ovarian cancer at two UK NHS Cancer Centres over a 5-year period (December 2009 to August 2015). Standard of care treatment was defined as a combination of cytoreductive surgery and if indicated platinum-based chemotherapy (combination or single-agent). Sixty-five percent of patients aged 65 and above received standard of care treatment. Increasing age was associated with lower rates of receiving standard of care (35% > 80 years old versus 78% of 65–69-year-olds, p = 0.000). Older women were less likely to complete the planned chemotherapy course (p = 0.034). The oldest women continue to receive lower rates of standard care compared to younger women. Once adjusted for Federation of Gynaecology and Obstetrics (FIGO) stage, Eastern Cooperative Oncology Group (ECOG) performance status and first-line treatment received, age was no longer an independent risk factor for poorer overall survival. Optimisation of vulnerable patients utilising a comprehensive geriatric assessment and directed interventions to facilitate the delivery of standard of care treatment could help narrow the survival discrepancy between the oldest patients and their younger counterparts.

Download Full-text

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

Cancer Immunology Immunotherapy ◽

10.1007/s00262-012-1261-1 ◽

2012 ◽

Vol 61 (11) ◽

pp. 2033-2044 ◽

Cited By ~ 89

Author(s):

Hilko Ardon ◽

Stefaan W. Van Gool ◽

Tina Verschuere ◽

Wim Maes ◽

Steffen Fieuws ◽

...

Keyword(s):

Dendritic Cell ◽

Phase I ◽

Standard Of Care ◽

Newly Diagnosed ◽

Autologous Dendritic Cell ◽

Care Treatment ◽

Standard Of Care Treatment ◽

Newly Diagnosed Glioblastoma

Download Full-text

Do elderly women with endometrial cancer receive standard of care treatment?

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00905-7 ◽

2021 ◽

Vol 162 ◽

pp. S139

Author(s):

Michelle Soloff ◽

Aaron Nizam ◽

Ariel Kredentser ◽

Bethany Bustamante ◽

Weiwei Shan ◽

...

Keyword(s):

Endometrial Cancer ◽

Elderly Women ◽

Standard Of Care ◽

Care Treatment ◽

Standard Of Care Treatment

Download Full-text

STEM-24. RADIATION-INDUCED EXTRACELLULAR VESICLE (EV) RELEASE OF miR-603 PROMOTES IGF1-MEDIATED STEM CALL STATE IN GLIOBLASTOMAS

Neuro-Oncology ◽

10.1093/neuonc/noaa215.841 ◽

2020 ◽

Vol 22 (Supplement_2) ◽

pp. ii201-ii201

Author(s):

Valya Ramakrishnan ◽

Beibei Xu ◽

Johnny Akers ◽

Thien Nguyen ◽

Jun Ma ◽

...

Keyword(s):

Recipient Cell ◽

Alkylating Agents ◽

Acquired Resistance ◽

Standard Of Care ◽

Extracellular Vesicle ◽

Cross Resistance ◽

Dna Damages ◽

Care Treatment ◽

Standard Of Care Treatment ◽

The Impact

Abstract INTRODUCTION Release of exosomes and extracellular vesicles (EV) by glioblastomas plays key roles in modulating the tumor microenvironment and therapeutic response. Studies to date have largely focused on the impact of EV and exosomes on the recipient cell. Here, we demonstrate that EV-mediated export of a master-regulatory miRNA has fate-determining impacts on the cell releasing the EVs. METHODS microRNA (miRNA) profiling was performed using clinical glioblastoma specimens from the same patients derived pre- and post-standard of care treatment. Mechanism mediating altered miRNA homeostasis were assessed. RESULTS While the levels of nearly all miRNAs remained unchanged after standard-of-care treatment, decreased levels of few, select miRNAs were observed, including miR-603. In response to ionizing radiation (IR), but not temozolomide (TMZ), glioblastoma cell lines exhibited a time-dependent decrease in miR-603 levels. While miR-603 biogenesis and degradation remained unchanged after IR, IR induced an increase in EV-mediated export of miR-603. Profiling of miR-603 targets revealed that miR-603 repressed the insulin-like growth factor 1 (IGF1) and IGF1 receptor (IGF1R), genes required to maintain the cancer stem cell (CSC) state, as well as MGMT, the gene encoding a DNA repair protein that detoxifies temozolomide (TMZ) induced DNA damages. IR induced export of miR-603 de-repress IGF1/IGF1R to promote radiation resistance and de-repress MGMT to promote cross-resistance to TMZ and CCNU. Ectopic miR-603 expression overwhelmed cellular capacity for miR-603 export and synergized with the tumoricidal effects of IR and temozolomide (TMZ). CONCLUSIONS Radiation stimulated EV-mediated export of miR-603 to facilitate acquired resistance to IR and cross-resistance to DNA alkylating agents.

Download Full-text

A meta-analysis of efficacy and safety of genotype-guided versus standard of care treatment strategies in selecting antiplatelet therapy in patients with acute coronary syndrome

Catheterization and Cardiovascular Interventions ◽

10.1002/ccd.28860 ◽

2020 ◽

Cited By ~ 1

Author(s):

Salik Nazir ◽

Keerat R. Ahuja ◽

Hafeez U. H. Virk ◽

Ahmed Elzanaty ◽

Tayyab A. Waheed ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Antiplatelet Therapy ◽

Meta Analysis ◽

Treatment Strategies ◽

Standard Of Care ◽

Efficacy And Safety ◽

Coronary Syndrome ◽

Care Treatment ◽

Standard Of Care Treatment

Download Full-text

The US–Latin America Cancer Research Network

JCO Global Oncology ◽

10.1200/go.20.52000 ◽

2020 ◽

Vol 6 (Supplement_1) ◽

pp. 56-56

Author(s):

Vidya Vedham ◽

Marianne K. Henderson ◽

Osvaldo Podhajcer ◽

Andrea Llera ◽

Marisa Dreyer Breitenbach ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Research ◽

Latin America ◽

Clinical Research ◽

Latin American ◽

Molecular Profiling ◽

Research Network ◽

Research Institutions ◽

Cancer Research Network ◽

The Us

PURPOSE The National Cancer Institute (NCI) Center for Global Health promotes global oncology research to reduce cancer burden worldwide. In 2009, NCI launched the Latin American Cancer Research Network (LACRN) to support a clinical cancer research network in Latin America. LACRN was started by a coalition of research institutions through bilateral collaborative agreements between the US Department of Health and Human Services and the governments of Argentina, Brazil, Chile, Mexico, and Uruguay. The LACRN is supported through a research contract to a study coordination center and subcontracts to 6 low- and middle-income country sites. The participating countries have a shared goal that meets the specific research needs of the regions. The overarching purpose of this endeavor is to implement high-quality standards for conducting clinical research studies and developing collaborative cancer research projects. METHODS NCI supported a clinical breast cancer project for LACRN, “Molecular profiling of breast cancer (MPBC) in Latin American women with stage II and III breast cancer receiving standard neo-adjuvant chemotherapy.” The molecular profiling of breast cancer study was conducted in 40 hospitals and research institutions across 5 countries with a study population of approximately 1,400 patients. RESULTS AND CONCLUSION Establishing a comprehensive network in Latin America and their research institutions yielded an incredible research resource that can be used in future studies, driven by the network. Throughout the process of developing and implementing studies, LACRN helped identify key elements of the functionality of research networks, such as the pivotal role of institutional and government commitment for sustainability; the importance of building multidisciplinary teams, transparent communications, and training; the ability to combine translational, epidemiology, and clinical research to close research gaps; and the application of new technologies to standard cancer clinical care.

Download Full-text